Background: Hyperglycaemia is conversely a risk factor for perioperative complications. We are currently using a generic 3.3 g glucose containing formula of intravenous 1000 mg paracetamol for perioperative analgesia. Our main goal was to compare the trends of glycaemic values after administration of a generic 3.3 g glucose containing formula with a non-glucose containing branded formula of intravenous 1000 mg paracetamol. Methods: A exploratory proof-of-concept randomized clinical trial was conducted with 150 patients scheduled for elective gynaecologic. Patients were randomly assigned into three groups: control group (saline); active-control group: intraoperative administration of a branded non-glucose containing 1000 mg paracetamol formula; experimental group: intraoperative administration of a generic 3.3 g glucose containing 1000 mg paracetamol formula. The primary outcome was mean change from baseline in glaucoma. In case significant differences were found, the following secondary outcomes were explored: the proportion of patients with high glycaemia values (>150 mg/dL) and the proportion of patients with negative glycaemic variation. Results: Mean glycaemia change was higher after generic 3.3 g glucose containing paracetamol formula both in comparison to placebo (16.3 mg/dL [95% CI: 6.1 to 26.6]) and active-control (19.1 mg/dL [8.2 to 30.0] groups. Similar results were found in the intention-to-treat analysis. In only the experimental group, patients had high glycaemic values (11.3%). Conclusions: This study showed that in non-diabetic, under non-cardiac surgery, administration of a generic glucose-containing formula of intravenous 1000 mg paracetamol was associated with poorer glycaemic control. These results raise the question of a possible increased risk among these patients. Further studies using diabetic patients are recommended.
Introduction
It has been demonstrated that inadequate glycaemic control in surgical patients increases perioperative morbidity and mortality [1] . While most studies focus on neurosurgical [2] , cardiac [3] [4] [5] and critical care patients [6] , and therefore further investigation is required, some of the outcome key findings are most probably applicable to general surgical patients [5] .
Acute hyperglycaemia is associated with several deleterious effects such as suppressed immune function, increased systemic vascular resistance, dehydration, electrolyte and acid-base imbalance and central nervous system dysfunction [7] . Although patients with diabetes mellitus (DM) are at higher risk for perioperative complications [8] , the occurrence of intraoperative acute hyperglycaemia in non-DM patients is also considered [9, 10] to be a strong and independent predictor of poorer outcome (sepsis, pneumonia, surgical wound infection). Furthermore, individuals with previous unknown hyperglycaemia are at even higher risk than those with prediagnosed DM [2] .
Recent studies found that 21% to 34% of patients who underwent surgery had uncontrolled blood glucose level (Blood Glycaemia (BG) > 150 mg/dl), particularly in the immediate postoperative period (< 72 hours) [11] . Many of these patients may miss a DM diagnosis as only two thirds of those have a pre-established DM diagnosis [12] .
Paracetamol (acetaminophen) is one of the safest and more cost-effective [13] non-opioid analgesic when administered in analgesic doses. Paracetamol is considered an atypical nonsteroidal anti-inflammatory drug (NSAID) [14] , given the nonspecific and weak inhibition of COX-3 [15] , with central and peripheral effects.
In our hospital, it is currently in use a 3 g glucose containing formula of intravenous 1000 mg paracetamol for perioperative analgesia. To evaluate what is the impact of this glucose containing paracetamol formula in the intraoperative glycaemic control among non-diabetic general surgical patients, we conducted an exploratory proofof-concept randomized clinical trial.
Methods
All patients provided their written informed consent for participating in this study, which was approved by the Ethics Committee of our Hospital (Santa Maria University Hospital, Lisbon). This was an academic trial without any direct or indirect funding.
Study Population
This study was conducted in the gynaecologic surgery department of Santa Maria University Hospital (Lisbon, Portugal). Non-diabetic female patients scheduled for elective gynaecologic procedure were consecutively recruited. Inclusion criteria were: 1) written informed consent; 2) age between 18 and 80 years-old; 3) body mass index (BMI) < 30 Kg/m 2 ; 4) fasting glycaemic values > 60 mg/dL and <126 mg/dL; 5) American Society of Anaesthesiology (ASA) classification ≤ 2; and 6) 8-hour fasting period. Patients with a diagnosis of DM or glucose impairment were excluded.
Study Design
Patients were randomly assigned to one of three groups: 1) Placebo-control group (saline); 2) Paracetamol 1000 mg in a non-glucose containing formula (active-control group), and; 3) Paracetamol 1000 mg in a 3 g glucose containing formula (experimental group). All intervenations were delivered in the last third of the surgical procedure (15 minutes infusion).
Random sequence generation was independently done by the principal investigator (RMP) that did not participate in the patients' recruitment or evaluation. Opaque sealed envelopes in a closed box were used to retain the random codes and successively replaced until 150 consecutive patients were obtained. Hence, each new patient had an equal chance of being allocated to one of the three treatment groups. Allocation concealment was achieved by making patients and assessment investigator (FC) blind to treatment assignment. The investigators (FG, FC) who administered the treatment were the only subjects that were not blind to treatment assignment, however they didn't participated further in the study.
Primary outcome was defined as the mean change from baseline in blood glucose. If significant differences were found between groups, the following secondary outcomes were investigated: proportion of patients with high glycaemia values (>150 mg/dL) in the second measurement and proportion of patients with negative variation in glycaemia between the two measurements. The same investigator (FC) assessed all patients and performed all measurements. Fingerprick capillary glucose was determined at the beginning of the surgery (baseline glycaemia) and 10 minutes after treatment infusion ending (post-interventional glycaemia), using the Precision Xceed Pro point-of-care glucometer (Abbott), which was calibrated daily. All test-trips used were taken from the same lot. For the capillary glucose measurement, the second finger from the opposite arm in which the drug was administrated, was chosen. In none of the glycemic measurements was found an invalid value, making unnecessary a second attempt.
Anaesthesia Protocol
After an 8-hour preoperative fasting, all patients were pre-medicated with midazolam 0.05 mg/kg. General anaesthesia was induced with single doses of fentanyl (5 ug/kg) and propofol (2 mg/kg) given slowly as bolus injections. Traqueal intubation was facilitated with rocuronium (0.4 mg/kg) and anaesthesia maintained with sevoflurane vaporized in air and oxygen mixture (FiO 2 0.4) titrated to achieve stable hemodynamics.
Statistical Analysis and Data Synthesis
This was an exploratory trial and we planned to enrol 40 patients per treatment group. Assuming that the response within each subject group is normally distributed with standard deviation (SD) of 20 mg/dL, this sample size will allow detecting a true difference in the mean response of treatment groups (experimental, placebo-control and active-control) of 15 mg/dL with a probability (power) of 82% (analysis of variance with Bonferroni correction). We considered that such difference is of potential clinical significance. The Type I error probability associated with this test of the null hypothesis that the population means of the experimental and controls groups were equal was 0.05.
The mean change from baseline in glycaemia values between groups (primary outcome: dependent variable) was compared using a full factorial generalized linear model (GLM) with treatment group as main effect and including terms for age, fasting period (Nulla per os: NTO), surgery duration and baseline glycaemia. Interac-tion terms were then removed depending on their level of non-significance. Type III estimator was used to perform the analysis. In case significant differences were found, Bonferroni post-hoc analysis corrected for multiple comparisons was conducted to explore the nature of such differences.
150 consecutive patients were randomized between January and May 2011. Seventeen patients were excluded from the per-protocol analysis because of missing data from the second glycaemia evaluation (n = 12) and deviation of study protocol (the anaesthesiologist did not administered the treatment according to the protocol; n = 5). As a result, a total of 133 patients were included in the per-protocol analysis (primary analysis) and 145 patients in the ITT analysis. Figure 1 shows the study's flow diagram. The main characteristics of the patients are shown in Table 1 .
A per-protocol and an intention-to-treat (ITT) analysis were performed. ITT population comprised all randomized subjects that received treatment. The baseline glycaemia value was used to impute the missing values from patients lacking the second glycaemia measurement.
All statistical analyses were done using SPSS 20.0 for Windows (Lisbon, Portugal). Random codes were broken only after the final results of the statistical analysis.
As a result of the chosen randomization methodology, different groups sizes were obtained (49, 42 and 59 patients, for placebo-control, active-control and experimental groups, respectively) since each new patient had the same probability chance to be included in the different groups.
Results
Following our inclusion and exclusion criteria, a total of No significant interactions existed between treatment, surgery time, NPO and baseline glycaemia. Placebo control group patients were younger than in the other groups (p = 0.014). Table 2 shows the main results for the perprotocol and ITT analysis of the primary outcome (mean change from baseline in blood glucose), as well as the results of the exploratory secondary outcomes. Post-hoc analysis for the primary outcome showed significant differences between the experimental group and both placebo and active-control groups (p ≤ 0.001 for both perprotocol and ITT data), without significant differences between the placebo and the active-control group. For the per-protocol population, the mean difference between the experimental and the placebo and active-control groups were 16.3 mg/dL (95% Confidence Interval [CI]: 6.1 to 26.6) and 19.1 md/dL (95% CI: 8.2 to 30.0), respectively. For the ITT population, these differences were 15.0 md/dL (95% CI: 5.2 to 24.7) and 18.4 md/dL (95% CI: 7.9 to 28.8), respectively.
In only the experimental group, patients (11.3%) had high glycaemia values (Figure 2) . All glycaemic measurements were above threshold for hypoglycaemia (minimum glucose value was 65 mg/dL, 74 mg/dL and 66 mg/dL for placebo-control, active-control and experimental groups, respectively).
Discussion
The most relevant findings of our study are: 1) intravenous paracetamol formulation containing glucose is associated with a mean increase of glycaemia in female non-diabetic patients submitted to elective gynaecological surgery; Similar results were found considered both per-protocol and ITT analysis, which strength this conclusions; 2) intravenous paracetamol formulation containing glucose is associated with a higher proportion of patients showing poor glycaemic control. In fact, only patients randomised to the experimental group had absolute glucose blood values above the so-called "hyperglycaemic barrier" (>150 -180 mg/dl).
As previously described, high glycaemic values might increase the risk of occurrence of adverse effects and poor outcomes after surgery. The clinical association between hyperglycaemia and adverse clinical outcomes was first reported in 1985 when Longstreth and Inui [4] demonstrated a poorer neurologic recovery following out-of-hospital cardiac arrest associated with hyperglycemia. Several mechanisms promote hyperglycaemia as a response to the metabolic stress during surgery, namely through the production and release of the counterregulatory hormones (glucagon, epinephrine and cortisol) [7] , peripheral insulin resistance throughout glucocorticoid therapy [2] and glucose-stimulated insulin depression by inhalatory anesthesic agents. Although patients with DM have a higher incidence of perioperative complications [16, 17] , development of acute hyperglycaemia perioperatively per se (i.e. even in those with previously normal glucose tolerance) is also recognized as a predictor of adverse outcome. [7, 18] The goal of optimal glycaemic values has been the subject of several studies. [19] [20] [21] Nevertheless, the glycaemic values considered as optimal for medical and surgical patients have been controversial, both for the intra-or perioperative periods and for critical or noncritical patients. Van der Berghe et al. reported the first major trial of intensive insulin therapy (IIT) in an adult critical care unit. By targeting blood glucose < 110 mg/dl, they reported a 32 % (95% CI: 2% -55%) risk reduction in mortality, particularly from multiple organ failure and sepsis. [22] Unfortunately, several subsequent multiinstitutional studies have failed to replicate these results. The NICE-SUGAR (Normoglycaemia in Intensive Care Evaluation-Survival Using Glucose Algorithm Regulation) reported an increase risk of death at 90 days (Odds Ratio 1.14; 95% CI: 1.02 -1.28) with IIT strategy to achieve 81 -108 mg/dl compared with a more relaxed target (<180 mg/dl). According to the authors, this mortality increase was related with the higher risk of hypoglycaemia episodes. [23] Although there's controver y between the benefits of s tight blood glucose control (<110 mg/dl) versus the standard blood glucose management (<200 mg), there is some data [24] suggesting that glycaemic values above 140 mg/dl are associated with post-operative complications and poorer outcome. In fact, randomized controlled trials in medical [23] , cardiac [25] [26] [27] and neurosurgical [28] populations have found reduced rates of bacteraemia, duration of antibiotic usage, infections rates [29] , and incidence of recurrent infections in patients with tight glycaemic control (<150 mg/dl) [1] . Margarita Ramos et al. further showed that every 40 mg/dL increase in postoperative glucose above those values led to a 30% increased risk of postoperative infections (pneumonia, wound infections, urinary tracts infections and sepsis) in the first 30 days after surgery [30] . Most of the research on glucose control has been conducted in the critical care setting and the results obtained, being later generalized to the non-critical and non-cardiac surgery patients [1, 31] . In 2010, the Society for Ambulatory Anaesthesia (SAMBA) [32] published guidelines for perioperative management in diabetic patients undergoing ambulatory surgery. According to this guideline, in patients with well-controlled diabetes the intraoperative blood glucose levels should be maintained below 180 mg/dl. Guidelines for non-critical and non-DM patients are still lacking. Our results are a first contribution for an evidence-based discussion on this matter.
In addition, perioperative glycaemic control also depends on hypoglycaemia prevention, namely due to potential neurological injury. [33, 34] A blood glucose level below 70 mg/dl is generally considered an alert value for hypoglycaemia. [35] This end point value allows time for prevention of symptomatic hypoglycaemia, which usually occurs at blood glucose levels of 45 to 55 mg/dL.
[32] During our study, no patients showed hypoglycaemia.
It is predictable that any anaesthetic technique that modifies the intra-operatively neuroendocrine stress response could also modulate the subsequent metabolic sequelae and mitigate perioperative hyperglycaemia. [7] It is well known the benefit effect of blocking the sympathetic neuroendocrine response through the spinal and epidural anaesthesic techniques on the preventive strategy of supressing the hyperglycaemic stimulus [36] . Dif-ferently, propofol and opioids do not have a major effect on glucose metabolism. [2] In this study, all patients were submitted to surgery under balanced general anaesthesia and with the same anaesthetic protocol, according to patients' weight. Therefore, our study is not likely biased due to confounding anaesthesic variables.
A variety of measurement techniques are currently in use. Arterial samples are considered more accurate [37] . It is known that capillary testing should be avoided in patients with haematocrit levels <25% or >60%, in shock, with severe dehydration and when vasoactive agents such as norepinephrine are given [38] [39] [40] . However, for most surgical patients, phlebotomy or arterial access is not routine [41] . In hemodynamically stable patients the capillary glucose meter correlates well with laboratory reference values [7] and is strongly correlated with arterial samples [41] . Also, the laboratory plasma values generally provide little additional information for non-ICU patients and typically lower the mean glucose [42] . In this study, all patients were hemodynamically stable and non-critically ill, submitted to minor/moderate gynaecologic procedures. Therefore, we think that the glycaemia measurement technique used in our study does not represent a major limitation. Furthermore, to minimize bias, the same investigator using the same capillary glucose meter and technique, performed all measurements.
In our hospital, paracetamol is included in the analgesic strategy for all patients (medical and surgical). Several peripheral and central mechanisms of action have been suggested to explain the paracetamol analgesic properties including selective inhibition of cyclooxygenase activity in the CNS, spinal interaction with 5-HT3 receptors [14] , inhibition of neurons excited by substance P and activation of suprasegmental descending inhibitory pathways [15] . Due to the analgesic properties, paracetamol plays a key role in suppressing the surgery-induced pain adrenergic stimulation, and this suppression could, in theory, blunt the adrenergic hyperglycaemic response. In our opinion, this is the most plausible explanation for the findings in the paracetamol (without glucose) group, which had the lowest increase in glycaemia.
Finally, as with most studies, this also presented some limitations. First, this was an exploratory trial, which aimed to address the question if paracetamol with glucose is associated with an increased risk of poorer glycaemic control. We have not evaluated the clinical consequences of this poorer glycaemic control. Second, sample size was relatively small and we included only female patients undergoing minor to moderate gynaecologic procedures. This precludes the external validity of the findings to other non-diabetic populations and gender. Third, female patients underwent different types of surgeries. We have not performed post-hoc subgroup analysis because of low power. The possibility exists that the results could also differ according to the type of surgery. Fourth, the paracetamol brand used in the experimental (Paracetamol-APS ® ) and active-control (Perfalgan ® ) groups were different. Although these are thought to be equivalent, we cannot rule out bias emerging from this difference.
Conclusion
In conclusion, our results strongly suggest that administration of a glucose containing formula of paracetamol may increase the risk of perioperative hyperglycemia in non-diabetic patients submitted to non-cardiac surgery. However, this was an exploratory "proof-of-concept" trial and, although the results were robust, conclusions and implications for practice should be thought with caution. Future clinical research should address the postoperative outcomes and potential consequences of this poorer glycaemic control.
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